In the setting of severe trauma and sepsis, a breakdown in gut barrier function has been termed the """"""""motor of multi-system organ failure"""""""", but the underlying pathophysiology is unknown. This proposal is based upon a novel hypothesis that the loss of intestinal alkaline phosphatase (IAP) expression underlies the impairment in gut mucosal defense that occurs in critically ill patients. Although IAP is a well-known marker for crypt-villus differentiation, its physiological role has not been elucidated. We now believe that IAP represents a previously unrecognized gut defense mechanism that is designed to protect the organism from bacteria and toxins. The broad goals of this proposal are to (1) define the mechanisms by which IAP protects the organism from the luminal environment, (2) prove that this newly recognized component of the gut mucosal defense system actually exists in vivo, and (3) lay the groundwork for IAP-based therapies.
In Aim #1, in vitro model systems will be used to examine the mechanisms by which IAP protects the organism from luminal bacteria (e.g., Salmonella) and toxins (LPS). WT and IAP-expressing cells will be employed to identify the cellular targets for IAP, delineating its mechanism of action in protecting the host cell.
In Aim #2, in vivo model systems will be employed in WT and IAP KO mice in order to assess its functional role in regard to gut mucosal defense. Small intestinal ischemia and luminal Salmonella/LPS will be used to test the ability of the intestinal barrier to protect the host from infection, sepsis, and end organ damage.
Aim #3 is designed to establish the efficacy of utilizing IAP as a target in the context of a variety of disease states. The two models of sepsis/injury will be applied in the contexts of two susceptibility conditions in which IAP expression is lost, starvation and hypothyroidism. These studies in IAP KO and transgenic mice will allow us to determine the role that IAP plays in the gut barrier dysfunction that accompanies clinically relevant disease states. Taken together, these studies will elucidate the functions of IAP and its mechanisms of action, and are designed to provide the """"""""proof of principle"""""""" for IAP-targeted therapies that could be used in the clinical setting to maintain gut mucosal defense function. In lay terms, we will explore a previously unrecognized mechanism that the organism has developed to protect itself from harmful substances within the gastrointestinal tract, laying the groundwork for treatments that will aid critically-ill patients. The proposed studies will explore a previously unrecognized gut mucosal defense mechanism involving the intestinal brush border enzyme, intestinal alkaline phosphatase (IAP). The studies will elucidate the functions of IAP and its mechanisms of action, and are designed to provide the """"""""proof of principle"""""""" for IAP- targeted therapies that could be used in the clinical setting to maintain gut mucosal defense function.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK050623-13
Application #
7902256
Study Section
Gastrointestinal Mucosal Pathobiology Study Section (GMPB)
Program Officer
Carrington, Jill L
Project Start
1996-09-01
Project End
2011-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
13
Fiscal Year
2010
Total Cost
$359,775
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Malo, Madhu S; Moaven, Omeed; Muhammad, Nur et al. (2014) Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates. Am J Physiol Gastrointest Liver Physiol 306:G826-38
Alam, Sayeda Nasrin; Yammine, Halim; Moaven, Omeed et al. (2014) Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens. Ann Surg 259:715-22
Moss, Angela K; Hamarneh, Sulaiman R; Mohamed, Mussa M Rafat et al. (2013) Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate. Am J Physiol Gastrointest Liver Physiol 304:G597-604
Kaliannan, Kanakaraju; Hamarneh, Sulaiman R; Economopoulos, Konstantinos P et al. (2013) Intestinal alkaline phosphatase prevents metabolic syndrome in mice. Proc Natl Acad Sci U S A 110:7003-8
Nucera, Carmelo; Nehs, Matthew A; Nagarkatti, Sushruta S et al. (2011) Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16:296-309
Ramasamy, Sundaram; Nguyen, Deanna D; Eston, Michelle A et al. (2011) Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis. Inflamm Bowel Dis 17:532-42
Chen, Kathryn T; Malo, Madhu S; Beasley-Topliffe, Laura Kline et al. (2011) A role for intestinal alkaline phosphatase in the maintenance of local gut immunity. Dig Dis Sci 56:1020-7
Ebrahimi, Farzad; Malo, Madhu S; Alam, Sayeda Nasrin et al. (2011) Local peritoneal irrigation with intestinal alkaline phosphatase is protective against peritonitis in mice. J Gastrointest Surg 15:860-9
Chen, Kathryn T; Malo, Madhu S; Moss, Angela K et al. (2010) Identification of specific targets for the gut mucosal defense factor intestinal alkaline phosphatase. Am J Physiol Gastrointest Liver Physiol 299:G467-75
Malo, M S; Alam, S Nasrin; Mostafa, G et al. (2010) Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut 59:1476-84

Showing the most recent 10 out of 33 publications